# Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

> **NCT01162031** · PHASE2 · WITHDRAWN · sponsor: **Stanford University**

## Conditions studied

- Leukemia
- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Velcade

## Key facts

- **NCT ID:** NCT01162031
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no accrual
- **Last updated:** 2018-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01162031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01162031, "Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01162031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*